###begin article-title 0
###xml 170 178 <span type="species:ncbi:9606">patients</span>
Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 167 170 159 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 184 192 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 311 314 299 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 330 334 318 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF1</italic>
###xml 339 344 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2,</italic>
###xml 358 385 346 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; LT-&#945; (10.5 kb)</italic>
###xml 390 408 370 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (5.5 kb).</italic>
###xml 422 448 398 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2 and LT-&#945; (5.5 kb)</italic>
Circulating levels of tumor necrosis factor (TNF) and lymphotoxin-alpha (LT-alpha) have been associated with outcome in solid and hematologic malignancies. Within the TNF gene and the LT-alpha gene, polymorphisms have been identified at nucleotide positions -308 and +252, respectively. The variant alleles for TNF are designated TNF1 and TNF2, the ones for LT-alpha LT-alpha (10.5 kb) and LT-alpha (5.5 kb). Of interest, TNF2 and LT-alpha (5.5 kb) were shown to be associated with higher TNF and LT-alpha plasma levels than their counterparts. In the present study, we investigated the associations of the above mentioned polymorphisms with risk of relapse in childhood acute lymphoblastic leukemia (ALL) treated according to Berlin-Frankfurt-Munster (BFM) protocols.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Matched case-control study of 64 relapsed and 64 successfully treated non-relapsed childhood B-cell precursor ALL patients of standard and intermediate risk for treatment failure.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 49 58 49 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF1/TNF2</italic>
###xml 63 72 63 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2/TNF2</italic>
###xml 104 113 104 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF1/TNF1</italic>
###xml 178 179 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 206 231 206 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (10.5 kb/5.5 kb)</italic>
###xml 240 264 236 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (5.5 kb/5.5 kb)</italic>
###xml 297 323 289 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (10.5 kb/10.5 kb)</italic>
###xml 367 368 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 410 411 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The odds ratio (OR) for the combined category of TNF1/TNF2 and TNF2/TNF2 genotypes in comparison to the TNF1/TNF1 genotype was 1.17 (95 % confidence interval (CI) = 0.53 - 2.56, P = 0.697). The ORs for the LT-alpha (10.5 kb/5.5 kb) and the LT-alpha (5.5 kb/5.5 kb) genotypes with reference to the LT-alpha (10.5 kb/10.5 kb) genotype were 2.17 (95 % CI = 0.84 - 5.58, P = 0.107) and 0.5 (95 % CI = 0.09 - 2.66, P = 0.418), respectively.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
Our results do not suggest a major role of the investigated genetic polymorphisms with regard to risk of relapse in standard- and intermediate-risk childhood B-cell precursor ALL treated according to BFM protocols.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 266 267 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 268 269 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 457 458 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 459 460 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 501 509 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 763 766 744 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 869 870 850 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 871 872 852 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 918 922 899 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF1</italic>
###xml 958 962 939 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2</italic>
###xml 990 998 971 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 1264 1282 1237 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (10.5 kb)</italic>
###xml 1287 1304 1256 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (5.5 kb)</italic>
###xml 1305 1306 1270 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1318 1322 1283 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2</italic>
###xml 1331 1348 1296 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (5.5 kb)</italic>
###xml 1535 1539 1492 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2</italic>
###xml 1548 1565 1505 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (5.5 kb)</italic>
###xml 1645 1647 1598 1600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1648 1650 1601 1603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LT-alpha ; formerly TNF-beta) are cytokines with pleiotropic biological activities including, for example, the induction of programmed cell death and the regulation of immune cell proliferation and differentiation [1,2]. In a variety of studies, plasma levels of TNF or LT-alpha have been associated with outcome of certain autoimmune and infectious diseases as well as solid and hematologic malignancies [3-6]. Of interest, the secretion of TNF and LT-alpha is believed to be influenced by genetic polymorphisms within their genes located tandemly on the long arm of chromosome 6 within the MHC class III region. One of the best described of these polymorphisms is located at nucleotide position-308 within the TNF promoter region and affects a consensus sequence for a binding site of the transcription factor AP-2 [7,8]. Guanine at position-308 defines the common TNF1 allele and adenine the less common TNF2 allele. With regard to the LT-alpha gene, a polymorphism at nucleotide position 252 within the first intron was reported to influence LT-alpha plasma levels. This single nucleotide polymorphism (A252G) affects a phorbol ester-responsive element and distinguishes two alleles that have been designated LT-alpha (10.5 kb) and LT-alpha (5.5 kb)[9]. Both the TNF2 and the LT-alpha (5.5 kb) allele have been shown to correlate with elevated TNF or LT-alpha plasma levels. Besides a more severe outcome of autoimmune or infectious diseases and of particular interest to us, the TNF2 and the LT-alpha (5.5 kb) alleles have been associated with an adverse outcome in lymphoid malignancies [10-15].
###end p 10
###begin p 11
###xml 221 224 221 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 229 237 229 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
In the present study, we genotyped a matched case-control study group of 64 relapsed and 64 non-relapsed patients with childhood acute lymphoblastic leukemia (ALL) for the above described genetic polymorphisms within the TNF and LT-alpha genes in order to assess their predictive potential with regard to relapse in childhood ALL.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and study design
###end title 13
###begin p 14
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
The present study utilizes patients and data from the ALL-BFM 86 and ALL-BFM 90 multicenter trials of childhood ALL, conducted by the BFM study group. Design, conduct, analysis, and results of the ALL-BFM 86 and ALL-BFM 90 trials are described in detail elsewhere [16,17]. In both trials treatment was stratified into three branches (standard, intermediate, and high risk), mainly according to the leukemic cell mass estimate and treatment response. Treatment (in most cases induction, consolidation, reinduction, maintenance) consisted of intensive multiagent chemotherapy regimens employing standard drugs (e.g. prednisone, vincristin, daunorubicin, L-asparaginase, cyclophosphamide, cytarabine, 6-mercaptopurine, 6-thioguanin, methotrexate). Parts of the study group received cranial radiotherapy.
###end p 14
###begin p 15
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
###xml 313 320 <span type="species:ncbi:9606">patient</span>
The establishment of the present case-control study group has been described previously [18]. Briefly, relapsed patients from ALL-BFM 86 and ALL-BFM 90 with an available remission peripheral blood or bone marrow smear were included as cases into the study group if they could be matched to a successfully treated patient with an available remission peripheral blood or bone marrow smear (control individual) according to the following criteria: sex, age at diagnosis (+/- 6 months), white blood cell count (WBC) at diagnosis (+/- 10,000/mul), immunophenotype, trial, risk group, and treatment arm within the risk group of the respective trial. The latter criterion assured similarity of treatment between cases and controls. Controls had to have a minimum follow-up of 5 years. In case of relapses occurring later than 5 years of diagnosis, the follow-up for the control subject had to be at least as long as the time from date of initial diagnosis to date of relapse diagnosis in the case subject. If more than one control subject was available, the subject with the closest initial WBC at diagnosis with reference to the case subject was chosen. All spare remission peripheral blood or bone marrow smears were derived from official routine remission control examinations at time points during the first 6 month of treatment according to the study protocols of ALL-BFM 86 and 90.
###end p 15
###begin title 16
Genotype analysis
###end title 16
###begin p 17
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 127 135 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 260 263 256 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 429 430 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 535 543 531 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 752 754 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 928 932 916 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF1</italic>
###xml 980 983 968 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 1062 1066 1050 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2</italic>
###xml 1082 1083 1070 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1111 1119 1099 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 1177 1195 1161 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (10.5 kb)</italic>
###xml 1240 1257 1220 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (5.5 kb)</italic>
###xml 1310 1312 1286 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Genomic DNA was isolated from remission bone marrow or peripheral blood smears as described before [18]. Genotypes for TNF and LT-alpha were determined by polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP) analysis. The -308 TNF promoter polymorphism was analyzed by incorporating it into an Ncol restriction site that was created by introducing a single base change within the forward primer [7]. Primer sequences were: forward 5'-AGGCAATAGGTTTTGAGGGCCAT-3'; reverse 5'-TCCTCCCTGCTCCGATTCCG-3'. The LT-alpha polymorphism at nucleotide position +252 was analyzed by PCR amplification of a 368 bp fragment using the following primer pair: forward 5'-CTCCTGCACCTGCTGCCTGGATC-3'; reverse 5'-GAAGAGACGTTCAGGTGGTGTCAT-3' [10]. The amplified PCR products were digested overnight with Ncol and analyzed on 3.0 % Nusieve (TNF) or 3.0 % conventional agarose gels (LT-alpha). In case of presence of the TNF1 allele, the amplified 107 bp fragment from the TNF promoter is cut into two fragments of 87 and 20 bp, a fragment amplified from TNF2 remains uncut [7]. The 368 bp fragment from LT-alpha is unaffected by Ncol digestion in case of presence of a LT-alpha (10.5 kb) allele while a PCR product amplified from a LT-alpha (5.5 kb) allele is cut into two fragments of 133 and 235 bp [10].
###end p 17
###begin title 18
Statistical analysis
###end title 18
###begin p 19
###xml 289 292 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 303 311 303 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 512 513 506 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 562 565 556 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 570 578 564 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
After frequencies were calculated for descriptive purposes, correlation analyses (contigency coefficients for nominal data, Spearman correlation coefficients for ordinal data, Pearson correlation coefficients for continous data) were computed to investigate the interrelationships between TNF genotype, LT-alpha genotype and important clinical prognostic variables such as sex, age at diagnosis, WBC at diagnosis, and immunophenotype. Differences in the distribution of categorical variables were analyzed by Chi2 or Fisher's exact test. The association between TNF and LT-alpha genotypes and relapse of leukemia was examined by use of conditional logistic regression analysis to calculate odds ratios and their 95 % confidence intervals. Genotypes and genotype combinations were used as categorical variables in the analyses. The association of genotypes with time to relapse was analyzed by log rank tests. Computations were peformed using SAS software (SAS-PC Version 6.04, SAS Institute Inc., Cary, NC).
###end p 19
###begin title 20
Results and Discussion
###end title 20
###begin p 21
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF1</italic>
###xml 359 370 359 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(TNF1/TNF2)</italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2</italic>
###xml 512 530 508 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (l0.5 kb)</italic>
###xml 581 621 573 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(LT-&#945; (10.5 kb)/ LT-&#945; (5.5 kb)).</italic>
###xml 672 689 656 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (5.5 kb)</italic>
###xml 780 786 760 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 823 825 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 857 860 837 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 864 872 844 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 1066 1069 1042 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 1074 1082 1050 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 1208 1209 1180 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1252 1255 1224 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 1260 1268 1232 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 1344 1345 1312 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1398 1401 1366 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 1441 1449 1409 1413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 1631 1632 1595 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1672 1676 1636 1640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF1</italic>
###xml 1716 1734 1680 1694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (l0.5 kb)</italic>
###xml 1753 1757 1713 1717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2</italic>
###xml 1772 1789 1732 1745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (5.5 kb)</italic>
###xml 1801 1802 1755 1756 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1809 1810 1763 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1820 1822 1774 1776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1823 1825 1777 1779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1871 1874 1825 1828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 1879 1887 1833 1837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 2012 2015 1962 1965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 2020 2028 1970 1974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 2038 2040 1984 1986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 2111 2114 2057 2060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 2118 2126 2064 2068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 2149 2176 2091 2114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(TNF2 or LT-&#945; (5.5 kb))</italic>
###xml 2285 2287 2223 2225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 2364 2376 2302 2310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF/LT-&#945;</italic>
###xml 2455 2467 2389 2397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF/LT-&#945;</italic>
###xml 2663 2664 2593 2594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2814 2823 2744 2753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF1/TNF2</italic>
###xml 2832 2868 2762 2790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (10.5 kb)/LT-&#945; (5.5 kb)</italic>
###xml 2903 2915 2825 2833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF/LT-&#945;</italic>
###xml 3105 3114 3023 3032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2/TNF2</italic>
###xml 3122 3158 3040 3068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (5.5 kb)/ LT-&#945; (5.5 kb)</italic>
###xml 3234 3237 3144 3147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 3242 3250 3152 3156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 275 283 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 384 392 <span type="species:ncbi:9606">patients</span>
###xml 478 486 <span type="species:ncbi:9606">patients</span>
###xml 553 561 <span type="species:ncbi:9606">patients</span>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
###xml 2275 2283 <span type="species:ncbi:9606">patients</span>
Table 1 shows the distribution of matching variables and genetic analyses (DNA index and karyotype) in the 64 relapsed case subjects and the 64 successfully treated control subjects as previously described [18]. Within our entire study population of 128 patients, 84 (65.6%) patients were homozygous for the TNF1 allele, 41 (32.0%) patients were heterozygous (TNF1/TNF2) and 3 (2.3%) patients were homozygous for the TNF2 allele. With regard to LT-alpha, we observed 55 (43.0%) patients being homozygous for the LT-alpha (l0.5 kb) allele and 55 (43.0%) patients being heterozygous (LT-alpha (10.5 kb)/ LT-alpha (5.5 kb)). Eighteen (14.1%) patients were homozygous for the LT-alpha (5.5 kb) allele. The prevalences observed in our study are similar to the ones reported by Demeter et al. in a healthy German control sample [15]. Thus, it seems unlikely that TNF or LT-alpha genotypes are associated with the pathogenesis of childhood B-cell precursor ALL in the German population. With regard to clinically important variables, no particular associations between the TNF and LT-alpha genotypes and sex, age at diagnosis, WBC at diagnosis, immunophenotype, and risk group were observed (data not shown). Table 2 shows the prevalences of the investigated TNF and LT-alpha genotypes by case-control status of our study subjects. In addition, Table 2 contains information on the association of the -308 TNF promoter polymorphism and the intronic LT-alpha polymorphism at nucleotide position 252 with risk of ALL relapse in our study subjects. For both genotypes, no particular associations with risk of ALL relapse were observed (Table 2). As reported in previous studies, the TNF1 allele was significantly linked to the LT-alpha (l0.5 kb) allele as was the TNF2 allele to the LT-alpha (5.5 kb) allele (Chi2 test; P < 0.01) [10,13]. The strong association between polymorphic TNF and LT-alpha alleles made Warzocha and colleagues to use haplotypes for their outcome analysis in a study on lymphoma outcome related to TNF and LT-alpha alleles [10]. In their study, the authors found that the presence of at least two TNF or LT-alpha high-producer alleles (TNF2 or LT-alpha (5.5 kb)) was an independent risk factor for progression-free survival in adult diffuse large-cell lymphoma patients [10]. When we analyzed the risk of relapse conferred by so-called high-producer TNF/LT-alpha haplotypes (at least two high-producer alleles) in comparison to low-producer TNF/LT-alpha haplotypes (less than two high-producer alleles) we also failed to observe any meaningful association in our study population (odds ratio (OR) = 1.08; 95% confidence interval (CI) = 0.51 - 2.30; P = 0.841). However, based on the discordant pairs observed in our study, we only had a power of 80% to detect risks greater than 3.0 conferred by the TNF1/TNF2 and the LT-alpha (10.5 kb)/LT-alpha (5.5 kb) genotypes or by the high-producer TNF/LT-alpha haplotypes. Therefore, we neither can exclude smaller effects on treatment outcome mediated by the above mentioned exposures nor reasonably exclude clinically important effects of the rare TNF2/TNF2 or the LT-alpha (5.5 kb)/ LT-alpha (5.5 kb) genotype. Furthermore, we investigated possible influences of the analyzed TNF and LT-alpha genotypes on time to relapse or on site of ALL relapse (isolated bone marrow relapse; combined and isolated CNS relapse; combined and isolated testis relapse) and, as above, did not detect any associations.
###end p 21
###begin p 22
Characteristics of 64 relapsed case subjects and 64 successfully treated matched control subjects with acute lymphoblastic leukemia selected from trials ALL-BFM 86 and ALL-BFM 90
###end p 22
###begin p 23
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 111 112 111 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 247 248 247 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 283 284 283 284 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 286 287 286 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
a white blood cell count b common acute lymphoblastic leukemia c precursor B-cell acute lymphoblastic leukemia d therapy stratification in risk groups was mainly based on initial leukemic cell mass estimate and initial treatment response [16-18], e ratio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes
###end p 23
###begin p 24
Distribution of tumor necrosis factor (TNF) and lymphotoxin-alpha (LT-alpha) genotypes and their association with the occurrence of relapse in 64 case subjects and 64 successfully treated matched control subjects with acute lymphoblastic leukemia from ALL-BFM trials 86 and 90
###end p 24
###begin p 25
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 77 86 77 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF1/TNF2</italic>
###xml 91 100 91 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF2/TNF2</italic>
###xml 111 112 111 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 153 178 153 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (10.5 kb/5.5 kb)</italic>
###xml 183 207 179 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (5.5 kb/5.5 kb)</italic>
###xml 226 252 218 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (10.5 kb/10.5 kb)</italic>
###xml 282 283 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
a odds ratio b confidence interval c odds ratio for the combined category of TNF1/TNF2 and TNF2/TNF2 genotypes d odds ratio for the combined category of LT-alpha (10.5 kb/5.5 kb) and LT-alpha (5.5 kb/5.5 kb) with reference to LT-alpha (10.5 kb/10.5 kb) was 1.5 (95% CI = 0.68-3.32; P = 0.317)
###end p 25
###begin p 26
###xml 270 273 270 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 278 286 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 499 502 495 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 507 515 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 597 615 589 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945; (10.5 kb)</italic>
###xml 656 658 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1003 1006 991 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 1011 1019 999 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
###xml 717 725 <span type="species:ncbi:9606">patients</span>
From the data presented in this study, we are not able to generalize our findings to childhood ALL patients of all immunophenotypic subgroups since we only investigated common and pre-B-cell ALLs. Similarly, we were not able to assess an association of the investigated TNF and LT-alpha genotypes on risk of relapse in high-risk childhood ALL patients since also these patients were not part of our study group. The latter point may be interesting to pursue as Demeter and colleagues, in a study on TNF and LT-alpha polymorphisms in chronic lymphocytic leukemia (CLL), detected an increase of the LT-alpha (10.5 kb) allele at more advanced disease stages [15]. Thus, additional investigations including childhood ALL patients of all clinically relevant subgroups are needed to lead to more conclusive results. However, for the subgroup of childhood B-cell precursor ALL of standard and intermediate risk treated according to BFM regimens that was analyzed in the present study, the investigated genetic TNF and LT-alpha polymorphisms do not seem to play a major role with regard to risk of relapse.
###end p 26
###begin title 27
Conclusions
###end title 27
###begin p 28
###xml 159 162 159 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 217 225 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LT-&#945;</italic>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
In a matched case-control group of 64 relapsed and 64 successfully treated childhood B-cell precursor ALL patients (all at standard or intermediate risk), the TNF gene polymorphism at nucleotide position -308 and the LT-alpha gene polymorphism at nucleotide position +252 were not significantly related with risk of ALL relapse. Our results do not suggest a major role of the investigated genetic polymorphisms with regard to risk of relapse in childhood B-cell precursor ALL of standard and intermediate risk treated according to BFM protocols.
###end p 28
###begin title 29
Competing interests
###end title 29
###begin p 30
None declared.
###end p 30
###begin title 31
Pre-publication history
###end title 31
###begin p 32
The pre-publication history for this paper can be accessed here:
###end p 32
###begin p 33

###end p 33
###begin title 34
Acknowledgments
###end title 34
###begin p 35
###xml 17 29 <span type="species:ncbi:9606">participants</span>
We thank all the participants of the ALL-BFM 86 and 90 studies for their cooperation. This work was partly supported by the "Madeleine-Schickedanz-Kinderkrebsstiftung", Furth, Germany.
###end p 35
###begin article-title 36
 The tumor necrosis factor ligand and receptor families.
###end article-title 36
###begin article-title 37
 Mechanism of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
###end article-title 37
###begin article-title 38
###xml 89 97 <span type="species:ncbi:9606">patients</span>
 Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
###end article-title 38
###begin article-title 39
###xml 131 139 <span type="species:ncbi:9606">patients</span>
Plasma levels of tumor necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.
###end article-title 39
###begin article-title 40
###xml 88 96 <span type="species:ncbi:9606">patients</span>
 Endogenous tumor necrosis factor as a predictor of doxorubicin sensitivity in leukemia patients.
###end article-title 40
###begin article-title 41
###xml 92 100 <span type="species:ncbi:9606">patients</span>
 The tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
###end article-title 41
###begin article-title 42
###xml 33 38 <span type="species:ncbi:9606">human</span>
 Single base polymorphism in the human tumor necrosis factor alpha (TNFalpha) gene detectable by NcoI restriction of PCR product.
###end article-title 42
###begin article-title 43
 Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease.
###end article-title 43
###begin article-title 44
###xml 113 118 <span type="species:ncbi:9606">human</span>
 Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production.
###end article-title 44
###begin article-title 45
 Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome.
###end article-title 45
###begin article-title 46
 Genetics of tumor necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases.
###end article-title 46
###begin article-title 47
 Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease.
###end article-title 47
###begin article-title 48
###xml 138 146 <span type="species:ncbi:9606">patients</span>
A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis.
###end article-title 48
###begin article-title 49
 Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis.
###end article-title 49
###begin article-title 50
 Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia.
###end article-title 50
###begin article-title 51
###xml 71 79 <span type="species:ncbi:9606">patients</span>
 Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.
###end article-title 51
###begin article-title 52
 Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial radiotherapy: results of trial ALL-BFM 90.
###end article-title 52
###begin article-title 53
 Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study.
###end article-title 53

